Delivery Order W81K0224D0009-W81K0225FA091
Award Date 7/1/25
Potential Completion Date 9/28/25
Potential Value $4.5K
Funding Federal Agency
Contracting Federal Agency
Ultimate Awardee
NAICS Category
PSC Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
South Korea
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Health Agency awarded a $40,945.50 firm fixed-price delivery order to Revvity Omics Inc. (doing business as Perkinelmer Genetics) on September 29, 2024, for newborn screening testing services at Brian D. Allgood Army Community Hospital (BDAACH) in South Korea. This task order covers the base performance period from September 29, 2024, through September 28, 2025, and was awarded without a small business set-aside designation. The delivery order is issued under a larger single-award...
- This federal contract award is for newborn screening testing services provided by Revvity Omics Inc., doing business as Perkinelmer Genetics, to the Defense Health Agency (DHA) for the Brian D. Allgood Army Community Hospital (BDAACH) in South Korea. The contract is a firm fixed price delivery order under a larger indefinite delivery, indefinite quantity (IDIQ) contract awarded to Perkinelmer Genetics in 2019 by the DHA to provide newborn screening for Army medical facilities in Korea. The...
- The Defense Health Agency issued a $42,993 delivery order to Revvity Omics Inc. on September 29, 2025, for newborn screening testing services at Brian D. Allgood Army Community Hospital in South Korea, with completion by September 28, 2026. This delivery order is issued under a single-award Indefinite Delivery Contract valued at $301,668 with a base period from September 29, 2024, through September 28, 2025, and four one-year option periods extending through September 28, 2029. Place of...
- The Defense Health Agency awarded a firm fixed-price purchase order valued at $848,688 to Revvity Omics Inc. (doing business as PerkinElmer Genetics) on October 1, 2024, for newborn genetic testing services at William Beaumont Army Medical Center in Fort Bliss, Texas. The contract extends through September 30, 2029, with no small business set-aside designation. The award fulfills a Department of the Army Medical Command solicitation issued in July 2024 seeking a contractor to conduct a...
- The Department of the Army Medical Command awarded a $34,329.12 firm fixed price delivery order to Perkinelmer Genetics, Inc. for newborn screening testing services in support of the Brian D. Allgood Army Community Hospital and 121st Combat Support Hospital in Korea. The testing will be conducted under an Other Transaction for Prototype III agreement and is to be completed by September 28, 2023. Perkinelmer Genetics, Inc. is a subsidiary of Revvity Inc., which operates in the medical imaging...
- This firm fixed-price purchase order contract was awarded by the Department of the Army Medical Command to Revvity Omics Inc., doing business as Perkinelmer Genetics, for comprehensive newborn screening services. The contract has a potential value of $375,186.00 and a completion date of September 30, 2016. Perkinelmer Genetics, a for-profit subsidiary of Revvity Inc., specializes in medical imaging and genetic testing services. This contract supports the military healthcare system by providing...
- This is a firm fixed price contract awarded by the U.S. Department of Defense's Medical Command (MEDCOM) to Revvity Omics Inc., doing business as Perkinelmer Genetics, for $91,840.00. The contract is for newborn screening services, which involves testing infants for conditions such as galactosemia, hypothyroidism, sickle cell disease, and cystic fibrosis. Perkinelmer Genetics is the prime contractor and does not appear to have any major subcontractors. This contract is not associated with a...
- This delivery order against the Defense Health Agency's Newborn Screening Testing Services contract awards Perkinelmer Genetics, Inc. $8,918.84 to provide newborn screening testing services for the Brian D. Allgood Army Community Hospital in South Korea from June 1, 2023 through September 28, 2023. As the prime contractor, Perkinelmer Genetics will perform the testing at its own facilities, with oversight from the Defense Health Agency. The contract has no set-aside designation and utilizes a...
- The Defense Health Agency awarded a purchase order to Revvity Omics Inc. for $165,711.65 on October 1, 2021, for newborn screening services. The order is firm fixed-price with no small business set-aside. Performance occurs at Fort Irwin, California, with an ultimate completion date of September 30, 2026. The procurement involves comprehensive newborn screening panels for early detection of genetic and metabolic conditions. The originating solicitation was posted August 18, 2021, with a due date...
- This is a firm fixed-price contract awarded by the U.S. Army Medical Command (MEDCOM) to Revvity Omics Inc., doing business as Perkinelmer Genetics, for $99,600.00. The contract is for newborn screening services, which involve testing infants for conditions such as galactosemia, hypothyroidism, sickle cell disease, and cystic fibrosis. Perkinelmer Genetics, a subsidiary of Revvity Inc., is the prime contractor and will perform the screening tests at its own laboratories. This contract does not...